Psychedelics Promote Structural and Functional Neural Plasticity
Calvin Ly,Alexandra C. Greb,Lindsay P. Cameron,Jonathan M. Wong,Eden V. Barragan,Paige C. Wilson,Kyle F. Burbach,Sina Soltanzadeh Zarandi,Alexander Sood,Michael R. Paddy,Whitney C. Duim,Megan Y. Dennis,A. Kimberley McAllister,Kassandra M. Ori-McKenney,John A. Gray,David E. Olson +15 more
Reads0
Chats0
TLDR
It is reported that, like ketamine, serotonergic psychedelics are capable of robustly increasing neuritogenesis and/or spinogenesis both in vitro and in vivo.About:
This article is published in Cell Reports.The article was published on 2018-06-12 and is currently open access. It has received 436 citations till now.read more
Citations
More filters
Journal ArticleDOI
Psychédéliques, psychothérapie et symbolisation : une revue de littérature dans le champ de la dépression
Etienne Artru,Thomas Rabeyron +1 more
TL;DR: In this paper, a revue de litterature concernant les psychedeliques dits classiques (LSD, psilocybine, DMT and mescaline) and their use in psychotherapie dans le champ de la depression is presented.
Journal ArticleDOI
Psychedelics and Neural Plasticity: Therapeutic Implications
TL;DR: For example, the authors discussed the effects of psychedelics on gene expression, gene expression and dendrites, and psychedelic effects on microcircuitry and brain-wide circuits, as well as unanswered basic neuroscience questions addressable with future studies.
Journal ArticleDOI
MDMA Is Not Ecstasy: The Production of Pharmaceutical Safety through Documents in Clinical Trials.
TL;DR: This article tracks the production of safety through the inter-connected work of clinical documents, which manage both which bodies are allowed to absorb the drug and which bodily events count as effects, and argues that MDMA's safety emerges from the careful management of relations through these documentary practices.
Journal ArticleDOI
Modulation of DNA methylation and protein expression in the prefrontal cortex by repeated administration of D-lysergic acid diethylamide (LSD): Impact on neurotropic, neurotrophic, and neuroplasticity signaling
Antonio Inserra,Antonella Campanale,David Cheishvili,Sergiy Dymov,Amy Wong,Nathalie Marcal,Robert A. Syme,Lorne Taylor,Danilo De Gregorio,Timothy E. Kennedy,Moshe Szyf,Gabriella Gobbi +11 more
TL;DR: In this article , the effects of repeated lysergic acid diethylamide (LSD) on whole-genome DNA methylation and protein expression in the mouse prefrontal cortex (PFC) were investigated.
Posted ContentDOI
d-Lysergic acid diethylamide has major potential as a cognitive enhancer
Felipe Augusto Cini,Isis M. Ornelas,Encarni Marcos,Livia Goto-Silva,Juliana Damieli Nascimento,Sergio Ruschi,José Alexandre Salerno,Karina Karmirian,Marcelo N. Costa,Eduardo Bouth Sequerra,Draulio de Araujo,Luís Fernando Tófoli,César Rennó-Costa,Daniel Martins-de-Souza,Amanda Feilding,Stevens K. Rehen,Sidarta Ribeiro +16 more
TL;DR: It is shown that a single dose of d-LSD, a potent serotonergic agonist, increased novel object preference in young and adult rats several days after treatment, and a computational model of synaptic connectivity in the hippocampus and prefrontal cortex suggests that d- LSD enhances novelty preference by combining local synaptic changes in mnemonic and executive regions, with alterations of long-range synapses.
References
More filters
Journal ArticleDOI
Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.
Harvey Whiteford,Harvey Whiteford,Louisa Degenhardt,Louisa Degenhardt,Juergen Rehm,Juergen Rehm,Amanda J Baxter,Amanda J Baxter,Alize J. Ferrari,Alize J. Ferrari,Holly E. Erskine,Holly E. Erskine,Fiona J Charlson,Fiona J Charlson,Rosana E. Norman,Rosana E. Norman,Abraham D. Flaxman,Nicole E. Johns,Roy Burstein,Christopher J L Murray,Theo Vos +20 more
TL;DR: The Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) as discussed by the authors was used to estimate the burden of disease attributable to mental and substance use disorders in terms of disability-adjusted life years (DALYs), years of life lost to premature mortality (YLLs), and years lived with disability (YLDs).
Journal ArticleDOI
Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report
A. John Rush,Madhukar H. Trivedi,Stephen R. Wisniewski,Andrew A. Nierenberg,Jonathan W. Stewart,Diane Warden,George Niederehe,Michael E. Thase,Philip W. Lavori,Barry D. Lebowitz,Patrick J. McGrath,Jerrold F. Rosenbaum,Harold A. Sackeim,David J. Kupfer,James F. Luther,Maurizio Fava +15 more
TL;DR: The acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial are described and compared.
Journal ArticleDOI
A simple practice guide for dose conversion between animals and human.
Anroop B. Nair,Shery Jacob +1 more
TL;DR: This review provides basic information about translation of doses between species and estimation of starting dose for clinical trials using allometric scaling and the method of calculation of injection volume for parenteral formulation based on human equivalent dose.
Journal ArticleDOI
Antidepressant effects of ketamine in depressed patients
Robert M. Berman,Angela Cappiello,Amit Anand,Amit Anand,Dan A. Oren,Dan A. Oren,George R. Heninger,Dennis S. Charney,Dennis S. Charney,John H. Krystal,John H. Krystal +10 more
TL;DR: A first placebo-controlled, double-blinded trial to assess the treatment effects of a single dose of an N-methyl-D-aspartate (NMDA) receptor antagonist in patients with depression suggests a potential role for NMDA receptor-modulating drugs in the treatment of depression.
Journal ArticleDOI
A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression
Carlos A. Zarate,Jaskaran Singh,Paul J. Carlson,Nancy E. Brutsche,Rezvan Ameli,David A. Luckenbaugh,Dennis S. Charney,Husseini K. Manji +7 more
TL;DR: Robust and rapid antidepressant effects resulted from a single intravenous dose of an N-methyl-D-aspartate antagonist; onset occurred within 2 hours postinfusion and continued to remain significant for 1 week.